Phase II trial of triple-receptor tyrosine 61 kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas; The final Analysis

Manmeet Ahluwalia

Phase II trial of triple-receptor tyrosine 61 kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas; The final Analysis

Manmeet Ahluwalia

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - May 2014
Event	ASCO Annual Meeting - Chicago, IL Duration: May 1 2014 → …

Conference

Conference	ASCO Annual Meeting
Period	5/1/14 → …

Disciplines

Medicine and Health Sciences

Cite this

@conference{1d621cbc1e7946bc9be236f881b1e242,

title = "Phase II trial of triple-receptor tyrosine 61 kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas; The final Analysis",

author = "Manmeet Ahluwalia",

year = "2014",

month = may,

language = "American English",

note = "ASCO Annual Meeting ; Conference date: 01-05-2014",

}